Welcome to our dedicated page for THERIVA BIOLOGICS SEC filings (Ticker: TOVX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Clinical-stage biotech disclosures can be dense. Theriva Biologics’ 10-K leans heavily on R&D milestones, licensing agreements and going-concern analyses, making it tough to spot what really moves the stock. If you have ever typed “Theriva Biologics SEC filings explained simply” or searched for the “Theriva Biologics annual report 10-K simplified,” you know the struggle. Even a single “Theriva Biologics quarterly earnings report 10-Q filing” can run hundreds of pages, while the “Theriva Biologics 8-K material events explained” notices often arrive when trial data shifts overnight.
Stock Titan’s AI-powered analysis cuts through that complexity. Our platform instantly summarizes each document, tags clinical trial milestones and flags liquidity updates, so understanding Theriva Biologics SEC documents with AI becomes straightforward. Real-time alerts ping the moment a “Theriva Biologics Form 4 insider transactions real-time” filing hits EDGAR, letting you view “Theriva Biologics insider trading Form 4 transactions” without digging. Side-by-side views link risk-factor language from the latest 10-K to subsequent 10-Q updates, turning raw text into context you can apply immediately.
Investors tracking the oncolytic adenovirus pipeline care about cash runway, trial enrollment rates and impending readouts. Our comprehensive coverage surfaces those details across every form type: 10-Q segments break down R&D spend; 8-Ks highlight collaboration amendments; the “Theriva Biologics proxy statement executive compensation” section shows how management is incentivized; and “Theriva Biologics executive stock transactions Form 4” entries reveal conviction levels. For deeper “Theriva Biologics earnings report filing analysis,” AI extracts quarter-over-quarter burn rates, while Smart Links connect narrative disclosures to the latest capitalization table. From first 8-K headline to final exhibit, our AI ensures you never miss a material detail.
Theriva Biologics, Inc. filed a Form 10-Q reporting total assets of $35.83 million and cash and cash equivalents of $12.12 million as of June 30, 2025. The company recorded a quarterly net loss of $13.06 million and a six-month net loss of $17.38 million, driven by a sharp increase in general and administrative expenses and continued R&D spending. In the period the company met primary survival and safety endpoints in its VIRAGE Phase 2b trial for lead candidate VCN-01, which triggered a contractual milestone obligation and contributed to an increase in contingent consideration to $10.16 million. The acquired in-process R&D (IPR&D) asset is carried at $19.62 million and was tested for impairment with no charge recorded. The company raised gross proceeds of approximately $7.5 million in a May 2025 offering and had cash of about $9.5 million in early August 2025, with management stating that current cash is expected to be sufficient into the first quarter of 2026. The 10-Q discloses substantial doubt about the Company’s ability to continue as a going concern and the need to obtain additional financing or strategic transactions to fund planned clinical activities.
Theriva Biologics, Inc. furnished a press release containing financial information for the quarter ended June 30, 2025, and attached that press release to this Current Report as Exhibit 99.1. The report also identifies an interactive data file as Exhibit 104.
The company states that the information in Item 2.02 and the attached press release is furnished and shall not be deemed to be "filed" for purposes of Section 18 of the Exchange Act and will not be incorporated by reference into other SEC filings. The Form 8-K is signed by Steven A. Shallcross, Chief Executive Officer and Chief Financial Officer. No financial figures are included in the Form text provided here.
Theriva Biologics (NYSE: TOVX) has announced a significant at-the-market (ATM) offering through an amended sales agreement with A.G.P./Alliance Global Partners. The company plans to offer up to $2.53 million worth of common stock through this facility.
Key details of the ATM offering include:
- Sales will be conducted through A.G.P./Alliance Global Partners as Sales Agent
- Sales Agent commission rate set at 3.0% of gross sales price per share
- Offering falls under the previously effective S-3 Registration Statement (File No. 333-279077) from September 2024
- Sales will be made through methods qualifying as "at the market offering" under Rule 415(a)(4)
The filing includes legal validation through Parsons Behle & Latimer's opinion on share validity. This offering provides Theriva with flexibility to raise capital as needed, though there's no obligation to sell any specific amount of shares.
Theriva Biologics (TOVX) has filed a prospectus supplement for an at-market offering of up to $2,534,352 worth of common stock through A.G.P./Alliance Global Partners. The offering is made under an Amended and Restated At Market Issuance Sales Agreement from February 2021, with subsequent amendments.
Key financial details:
- Previous sales: ~569,000 shares generating net proceeds of ~$3.6M in 2024
- Current stock price: $0.465 (as of June 17, 2025)
- Public float value: ~$12.9M based on 9,049,241 non-affiliate shares
- Sales agent commission: up to 3.0% of gross sales
The company, following its March 2022 acquisition of VCN Biosciences, focuses on developing cancer therapeutics. Their lead candidate, VCN-01, is an oncolytic adenovirus currently in Phase 2b trials for pancreatic cancer and Phase 1 studies for retinoblastoma and other solid tumors. The offering is limited by the one-third public float rule under Form S-3 requirements.
FAQ
What is the current stock price of THERIVA BIOLOGICS (TOVX)?
What is the market cap of THERIVA BIOLOGICS (TOVX)?
